La Jolla Price to Book vs. Total Debt

LJPC -- USA Stock  

USD 11.33  1.58  16.21%

The Drivers Module shows relationships between La Jolla's most relevant fundamental drivers and provides multiple suggestions of what could possibly affect the performance of La Jolla Pharmaceutical Company over time as well as its relative position and ranking within its peers. Please see also Stocks Correlation

La Jolla Pharmaceutical Total Debt vs. Price to Book Fundamental Analysis

La Jolla Pharmaceutical Company is currently regarded as number one stock in price to book category among related companies. It is rated third overall in total debt category among related companies making up about  5,144,138  of Total Debt per Price to Book.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.
La Jolla 
MV Per Share 
BV Per Share 
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principle payments will eventually prevent the firm from borrow excessively.
La Jolla 
Total Debt 
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
La Jolla Pharmaceutical Company is rated third overall in total debt category among related companies. Total debt of Biotechnology industry is now estimated at about 1.16 Billion. La Jolla retains roughly 154.89 Million in total debt claiming about 13% of stocks in Biotechnology industry.
Total debt  Workforce  Revenue  Capitalization  Valuation

La Jolla Fundamental Comparison